Drug reference

Bezlotoxumab

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1382

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Drug Action

Bezlotoxumab is a human monoclonal antitoxin antibody; it binds to Clostridioides difﬁcile toxin B and neutralises its activity, preventing recurrence of Clostridioides difﬁcile infection.

PDF page 1382

Indications And Dose

Prevention of recurrence of Clostridioides difficile infection in patients at high risk of reinfection ▶BY INTRAVENOUS INFUSION ▶Adult: 10 mg/kg for 1 dose, to be administered during the course of antibacterial therapy for Clostridioides difﬁcile infection

PDF page 1382

Safety

Side Effects

▶Common or very common Dizziness. dyspnoea. fatigue. fever. headache. hypertension. infusion related reaction. nausea

PDF page 1382

Pregnancy

Manufacturer advises avoid unless essential—limited information available.

PDF page 1382

Breast Feeding

Manufacturer advises avoid—no information available.

PDF page 1382

Dose and formulations

Directions For Administration

Manufacturer advises for intravenous infusion (Zinplava ®), give intermittently in Glucose 5 % or Sodium Chloride 0.9 %; dilute requisite dose to a concentration of 1–10 mg/mL with infusion ﬂuid; give over 60 minutes via a central venous catheter or peripheral catheter using a low-protein binding ﬁlter (0.2–5 micron). l HANDLING AND STORAGE Manufacturer advises store in a refrigerator (2–8 °C)—consult product literature for further information regarding storage conditions outside refrigerator and after preparation of the infusion.

PDF page 1382

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Solution for infusion EXCIPIENTS: May contain Polysorbates ELECTROLYTES: May contain Sodium ▶Zinplava (Merck Sharp & Dohme Ltd) A Bezlotoxumab 25 mg per 1 ml Zinplava 1g/40ml concentrate for solution for infusion vials | 1 vial P £2,470.00 (Hospital only)

PDF page 1382

Dose text by age group

Adult

10 mg/kg for 1 dose, to be administered during

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1382

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Bezlotoxumab

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1382

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Drug Action

Bezlotoxumab is a human monoclonal antitoxin antibody; it binds to Clostridioides difﬁcile toxin B and neutralises its activity, preventing recurrence of Clostridioides difﬁcile infection.

PDF page 1382

Indications And Dose

PDF page 1382

Safety

Side Effects

▶Common or very common Dizziness. dyspnoea. fatigue. fever. headache. hypertension. infusion related reaction. nausea

PDF page 1382

Pregnancy

Manufacturer advises avoid unless essential—limited information available.

PDF page 1382

Breast Feeding

Manufacturer advises avoid—no information available.

PDF page 1382

Dose and formulations

Directions For Administration

PDF page 1382

Medicinal Forms

PDF page 1382

Dose text by age group

Adult

10 mg/kg for 1 dose, to be administered during

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1382

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.